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Abstract
Background: Very few proteins encoded by the presumed non-coding RNA transcripts have been identified. Their
cellular functions remain largely unknown. This study identifies the tumor-suppressor function of a novel
microprotein encoded by the precursor of miR-34a. It consists of 133 amino acid residues, thereby named as
miPEP133 (pri-microRNA encoded peptide 133).
Methods: We overexpressed miPEP133 in nasopharyngeal carcinoma (NPC), ovarian cancer and cervical cancer cell
lines to determine its effects on cell growth, apoptosis, migration, or invasion. Its impact on tumor growth was
evaluated in a xenograft NPC model. Its prognostic value was analyzed using NPC clinical samples. We also
conducted western blot, immunoprecipitation, mass spectrometry, confocal microscopy and flow cytometry to
determine the underlying mechanisms of miPEP133 function and regulation.
Results: miPEP133 was expressed in normal human colon, stomach, ovary, uterus and pharynx. It was
downregulated in cancer cell lines and tumors. miPEP133 overexpression induced apoptosis in cancer cells and
inhibited their migration and invasion. miPEP133 inhibited tumor growth in vivo. Low miPEP133 expression was an
unfavorable prognostic marker associated with advanced metastatic NPC. Wild-type p53 but not mutant p53
induced miPEP133 expression. miPEP133 enhanced p53 transcriptional activation and miR-34a expression. miPEP133
localized in the mitochondria to interact with mitochondrial heat shock protein 70kD (HSPA9) and prevent HSPA9
from interacting with its binding partners, leading to the decrease of mitochondrial membrane potential and
mitochondrial mass.
Conclusion: miPEP133 is a tumor suppressor localized in the mitochondria. It is a potential prognostic marker and
therapeutic target for multiple types of cancers.
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Introduction
Non-coding RNAs (ncRNAs) include long non-coding
RNAs (lncRNAs, longer than 200 nucleotides) and small
non-coding RNAs (sncRNAs, shorter than 200 nucleo-
tides). MicroRNAs (miRNAs) are small ncRNAs consist-
ing of 20–24 nucleotides that negatively regulate the
stability and translational efficiency of target mRNAs
through binding to the 3′ untranslated regions [1]. Many
of them have been demonstrated to play crucial roles in
post-transcriptional gene regulation and cancer biology.
Genes of miRNAs were assumed to be incapable of en-
coding proteins. The biogenesis of miRNAs involves the
processing of larger primary miRNAs (pri-miRNAs) into
shorter pre-miRNAs, and the maturation of pre-miRNA
to produce active miRNAs [2]. Recent studies have dem-
onstrated that pri-miRNAs harbor short open reading
frames that can encode regulatory peptides, termed
miRNA-encoded peptides (miPEPs).
miPEPs that regulate growth and development were
first identified in plants. For example, miPEP171b of
Medicago truncatula and miPEP165a of Arabidopsis
thaliana are two plant miPEPs that positively regulate
the levels of their corresponding miRNAs [3]. The over-
expressed miPEPs or synthetic peptides specifically in-
crease the accumulation of the corresponding miRNAs
and enhance the inhibition of the miRNA-targeted genes
involved in root development. Therefore, it is hypothe-
sized that miPEPs specifically stimulate the transcription
of their associated miRNA to induce more pronounced
silencing of miRNA-targeted genes. However, it is un-
clear how miPEPs regulate the transcription machinery.
The molecular basis of miPEP specificity and activity are
unknown.
In animals, very few miPEPs have been identified till
date. Two peptides encoded by lncRNAs were identified
as important regulators of muscle physiology [4, 5].
Myoregulin (MLN) is encoded by a skeletal muscle-
specific lncRNA. It finely controls calcium uptake by
interacting with sarco/endoplasmic reticulum calcium
ATPase (SERCA) and plays a critical role in regulating
skeletal muscle performance. Another peptide of 34
amino acids named dwarf open reading frame (DWORF)
also interacts with SERCA and enhances cardiac muscle
contractility. A ncRNA-encoded microprotein named
Cancer-Associated Small Integral Membrane Open read-
ing frame 1 (CASIMO1) was recently identified as a 10
kDa protein encoded by a long non-coding RNA (NR_
029453). CASIMO1 interacts with squalene epoxidase to
regulate lipid droplet clustering and the proliferation of
breast cancer cells [6].
miR-34a is a tumor suppressor that inhibits the ex-
pression of about 700 target genes [7]. It plays an im-
portant role in suppressing tumorigenesis and is
downregulated in human cancers [8–10]. The expression
of miR-34a is mainly induced by p53 [11–13]. However,
accumulating evidence indicates that the level of miR-34a
can be regulated in a p53-independent manner. Due to its
anti-cancer functions, miR-34a has become one of the first
targets of miRNA therapy entering clinical trials [14, 15].
In this study, we report for the first time the identifica-
tion and functional characterization of a miPEP encoded
by the primary transcript of miR-34a. We named it
miPEP133 (pri-miR encoded peptide 133) because it
consists of 133 amino acid residues. Since miPEP133 is
highly expressed in the normal pharynx and significantly
downregulated in nasopharyngeal carcinoma (NPC), we
utilized the in vitro and in vivo models of NPC to study
the role of miPEP133 in tumorigenesis. NPC is a rare
type of head and neck cancer with 80,000 incident cases
and 50,000 deaths annually [16]. It is more prevalent in
southern China, southeastern Asian countries, northern
and northeastern Africa, Alaska, and western Canada
[17]. NPC is a leading cancer type in Malaysia [18]. NPC
is usually sensitive to radiotherapy. If diagnosed at early
stage it is considered curable with the 5-year survival
rate of about 80% [19]. However, more than 30% of pa-
tients will relapse with local recurrence or distant metas-
tases [20]. When NPC progresses into advanced disease,
the prognosis is very poor. The clinical management of
late stage NPC is extremely challenging. Research on the
tumor biology and etiology of NPC is very limited com-
paring to other more common cancer types. Our find-
ings on the regulation and functions of miPEP133 will
advance our knowledge on the roles of miPEPs in
tumorigenesis and tumor progression.
Methods
Human tissue samples
The NPC study protocol was approved by the Human
Research Ethics Committee of the First Affiliated Hos-
pital of Guangxi Medical University. The procedures are
in accordance with the Helsinki Decaration of 1975.
Written informed consent was obtained from all partici-
pants. Normal nasopharyngeal tissues adjacent to the
operation areas were collected from 8 patients. Ovarian
cancer sample collection was carried out with patient
consent and approved by the Human Investigations
Committee of Yale University School of Medicine. Tis-
sue samples were immediately frozen in liquid nitrogen
after resection and stored at − 80 °C until use. Clinical
information regarding the tissue samples is in
Additional file 1.
Cell lines and transfection
Human NPC cell lines HNE3, C666–1, CNE2, CNE1, 5-
8F, TWO3, and normal nasopharyngeal cell line NP69
were gifts from Guangxi Medical University Nasopha-
ryngeal Cancer Research Laboratory. SKOV3 and Hela
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cell lines were obtained from NCI Repository of Tumors
and Tumor Cell Lines. The ovarian cancer patient-
derived cell lines were provided by Dr. Gil Mor (Yale
University). Fallopian tube epithelial cell lines were gen-
erated previously [21] and provided by Dr. Ron Drapkin
(University of Pennsylvania). Cells were cultured in
DMEM containing 10% fetal bovine serum, 100 IU/ml
penicillin and 100 mg/ml streptomycin in humidified 5%
CO2 incubator at 37 °C. Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) was used for transfection according
to the manufacturer’s instruction. Lentivirus was pro-
duced as previously described to establish stable cell
lines with miPEP133 overexpression [22]. Puromycin
(1 μg/ml, Invitrogen) was used to maintain selective
pressure. Details about plasmids used in this study are
listed in Additional file 2.
Antibody production and evaluation
The production of anti-miPEP133 antibody was con-
ducted by GenScript (Piscataway, NJ, USA) as described
in Additional file 2. The antibody was evaluated by SDS-
PAGE and Coomassie Brilliant Blue staining. The speci-
ficity of the produced antibody against miPEP133 was
validated by ELISA.
Western blot and co-immunoprecipitation (co-IP)
Details of western blot and co-IP and the information of
antibodies are described in Additional file 2.
Quantitative PCR (QPCR)
Total RNA was extracted using TRIzol reagent (Invitro-
gen) and reverse-transcribed using Bulge-LoopTM
microRNA specific RTprimers (RiboBio, Guangzhou,
China) and M-MLV reverse transcriptase (Promega,
Madison, WI, USA). Real-time QPCR was performed on
a CFX96TouchTM system (Bio-Rad, Hercules, CA,
USA) using SYBR SuperMix (Bio-Rad). Mir-X miRNA
qRT-PCR TB Green Kit (Takara Bio, San Francisco, CA)
was used to detect miR-34a. RNU6B (U6) or GAPDH
were used as internal controls. Relative expression levels
were calculated using the 2 −ΔΔCT method. Primers
are listed in Additional file 2.
Mass spectrometry
The gel piece containing the 15 kDa protein band from
HEK293 cell lysate was excised and digested into peptide
fragments for mass spectrometry analysis. Mass spec-
trometry was performed as previously described [23].
For the identification of miPEP133-binging proteins, the
protein lysate of HEK293 cells expressing flag-labeled
miPEP133 or control empty vector was incubated with
anti-flag-tag antibody in the co-IP assay. Proteins in the
co-IP products were identified by mass spectrometry
analysis. The proteins that were identified in the IP
product of cells transfected with empty vector were ex-
cluded from the list of protein hits as background signals
(Additional file 4).
miPEP133 knockdown with siRNAs and CRISPR/Cas9-
mediated miPEP133 deletion
siRNAs were transfected using Lipofectamine RNAi-
MAX (Invitrogen) following the manufacturer’s instruc-
tion. miPEP133 siRNAs were synthesized by Ribo
Biotechnology (Guangzhou, China). The sequences of
siRNAs and the method of CRISPR/Cas9-mediated
miPEP133 deletion are listed in Additional file 2.
Cell fractionation and RNA/protein extraction
The cytoplasmic and nuclear RNA was extracted from
cells using Cytoplasmic and Nuclear RNA Purification kit
(Norgen BioTeck, Thorold, ON, Canada). Cell fraction-
ation and protein extraction were performed using Qpro-
teome Mitochondria Isolation kit (Qiagen, Germantown,
MD, USA) according to the manufacturer’s instruction.
Cell proliferation assay
Five thousand cells/well were plated in 96-well plates.
Cell viability reagent WST-8 (Abcam, Branford, CT) was
added to each well and incubated for 3 h at 37 °C at dif-
ferent time points. Optical density at 450 nm was mea-
sured using plate reader.
Flow cytometry analysis of apoptosis, cell cycle, and
mitochondrial membrane potential
Cells were stained according to the instruction of the
Annexin V-APC/7-AAD kit (Keygen Biotech, Nanjing,
China) and analyzed using FACSLyric Flow cytometry sys-
tem (BD, Franklin Lakes, NJ) to assess the apoptotic cell
populations. Cell cycle status was analyzed by propidium
bromide (PI) staining and flow cytometry as detailed in
Additional file 2. JC-1 mitochondrial membrane potential
assay kit (abcam) was used to stain the cells and assess
mitochondrial membrane potential by flow cytometer. A
potent mitochondrial uncoupler, carbonyl cyanide chloro-
phenylhydrazone (CCCP) was used as a positive control.
Migration assay and invasion assay
For wound healing assay, cells were seeded in 6-well
plates, grown to 90% confluence. A scratch wound was
made using a pipet tip. Wound width was measured
under microscope at 24 h. For the transwell migration
assay, cells were seeded into the transwells directly
(Corning, Corning, NY, USA) with 0.2 mL serum-free
medium. For the invasion assay, cells were seeded into
the Matrigel-coated transwells (Corning). The bottom
wells were filled with normal growth medium. After 24
h, cells in the upper wells were removed using a cotton
swab. The migrating/invading cells at the bottom of the
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transwells were fixed in 4% polyoxymethylene, stained
with crystal violet, and imaged in randomly chosen
fields. The stained cells were counted.
p53 response element luciferase reporter assay
PG13-luc (wt p53 binding sites) was a gift from Bert
Vogelstein (Addgene plasmid # 16442; http://n2t.net/
addgene:16442; RRID:Addgene_16,442). Renilla luciferase
control reporter pRL vector was purchased from Promega
(Madison, WI, USA). miPEP-133 or control vector was
co-transfected with PG13-luc plasmid. p53 transcriptional
activation was evaluated as previously described [24].
Immunofluorescence (IF) staining and confocal
microscopy
Formalin-fixed paraffin-embedded tissue sections were
deparaffinized and hydrated. Slides were submersed in 1X
citrate unmasking solution and heated in a microwave to
incubate at 95–98 °C for 10min. Cells were cultured on
chamber slides, fixed with 4% paraformaldehyde in PBS
for 10min at room temperature, and then washed with
PBS. The slides were incubated in blocking buffer (5%
normal serum and 0.3% Triton X-100 in PBS) for 60min
at room temperature. Primary antibodies were diluted in
antibody dilution buffer (1% BSA and 0.3% Triton X-100
in 1X PBS) and incubated with the slides overnight at
4 °C. Fluorochrome-conjugated secondary antibody was
incubated for 1 h at room temperature in the dark. Mount
medium with DAPI was used to mount the slides (Cell
Signaling, Danvers, MA, USA). The stained slides were
imaged using Leica SP8 Laser Scanning Confocal micro-
scope. Terminal deoxynucleotidyl transferase dUTP Nick-
End Labeling (TUNEL) staining was performed using In
Situ Cell Death Detection kit (Roche, Branford, CT, USA).
Luminescence-based ATP detection assay
Cells were counted using a hemocytometer. Cell suspen-
sion was mixed with the same volume of ATP assay re-
agent (Promega) to incubate for 10 min. The
luminescent signal was measured using GloMax Naviga-
tor plate reader (Promega).
Mouse model
Six-week-old female BALB/c-nude mice (Shanghai La-
boratory Animal, Shanghai, China) were subcutaneously
injected with 107 C666–1 cells that expressed miPEP133
or control lentivirus vector. Tumor width (W) and
length (L) were measured daily. Tumor volume was cal-
culated using formula V = π/6*L*W2. Three weeks after
injection, mice were euthanized to collect the tumors.
Statistics
Data were presented as the mean ± standard deviation.
All experiments included at least 3 biological repeats.
Student’s t-test, two-way ANOVA or chi-square test was
used in statistical analysis as specified for each experi-
ment. Kaplan–Meier analysis was employed for the sur-
vival analysis of two groups (miPEP133 low and high
groups). Survival was defined as time from diagnosis
until death or until time last followed. The differences in
the survival probabilities were estimated using the log-
rank test. P values less than 0.05 were considered to be
statistically significant.
Result
miPEP133 is a microprotein encoded by an ORF in the
pri-miRNA of miR-34a
miR-34a is encoded by MIR34AHG gene in the distal re-
gion of chromosome 1p. We identified a 402 bp ORF ad-
jacent to the MIR34A precursor sequence region
(Fig. 1a). We cloned the ORF into a plasmid vector and
transfected HEK293 cells. Using SDS-PAGE and Coomas-
sie blue staining, we detected a band at 15 kDa that was
enriched in the ORF-overexpressing cells compared to
the control cells (Fig. 1b). We excised the 15 kDa band
and digested the proteins into peptides for mass spec-
trometry analysis. Mass spectrometry analysis confirmed
the presence of 4 peptides that matched partial sequences
of the ORF protein product (Fig. 1c). This result demon-
strates that a 15 kDa protein as the product of this ORF
could be stably expressed in cells. We named this protein
product as pri-microRNA encodes peptide 133
(miPEP133) since it consists of 133 amino acid residues.
We selected a fragment of miPEP133 (PGPGGTSR
KEDPAA) to generate the synthetic peptide-carrier pro-
tein conjugate for raising a polyclonal rabbit antibody
against miPEP133. Using this antibody in western blot,
we detected a 15 kDa band in the cell lysate of HEK293
cells, which intensity was significantly increased in the
miPEP133-overexpressing cells (Fig. 1d). We also de-
tected a lower band in the lysate of the miPEP133-
overexpressing cells. We postulate that the lower band
represents a truncated form of miEPE133 that is cleaved
by protease. The overexpression of miPEP133 was also
confirmed at RNA level (Fig. 1e).
To verify the specificity of the anti-miPEP133 anti-
body, we designed three small interfering RNAs (siR-
NAs) to knock down the endogenous expression of
miPEP133 in HEK293 cells. Results of western blot and
RT-QPCR showed that two of the siRNAs (#1 and #3)
effectively inhibited miPEP133 mRNA expression and
significantly decreased the intensity of the 15 kDa pro-
tein band that was detected by the anti-miPEP133 anti-
body (Fig. 1f and g). We also generated two CRISPR/
Cas9-mediated deletions of miPEP133, MUT1 and
MUT2. They lacked 28 bp and 5 bp in the ORF of
miPEP133, respectively (Fig. 1h and Additional file 3: Fig.
S1), leading to the loss of the 15 kDa protein band in
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HEK293 cells (Fig. 1i). These results validated that the 15
kDa protein detected by this antibody was indeed miPEP133.
miPEP133 is naturally expressed by HEK293 cells. Cellular
fractionation of RNA showed that miPEP133 mRNA mainly
localized in the cytoplasm of HEK293 cells (Fig. 1j).
miPEP133 is expressed in human tissues
Next we assessed the expression of this newly identified
protein in different human tissues. Western blot of human
tissue homogenates demonstrated that miPEP133 was
highly expressed in human colon, ovary, stomach, uterus,
and pharynx tissues (Fig. 1k). Similar expression pattern
was observed in mouse tissues (Additional file 3: Fig. S2).
NP69 is a normal nasopharyngeal epithelial cell line
derived from human pharynx tissue. It is non-
tumorigenic and exhibits anchorage-dependent growth.
NP69 cells expressed miPEP133 mRNA that mainly lo-
calized in the cytoplasm (Fig. 2a). Six nasopharyngeal
cancer cell lines, HNE3, C666–1, CNE2, CNE1, 5-8F
and TWO3 showed significantly reduced levels of
miPEP133 protein comparing to NP69 (Fig. 2b and c).
In NPC samples we also detected significantly lower
levels of miPEP133 mRNA than normal nasopharyngeal
tissues (Fig. 2d). These findings led us to hypothesize
that miPEP133 was a nasopharyngeal endogenous pep-
tide that was downregulated during malignant trans-
formation, possibly playing a role as a tumor suppressor.
miPEP133 is a tumor suppressor that inhibits cancer cell
proliferation, migration and invasion
To determine whether miPEP133 acts as a tumor sup-
pressor, we overexpressed miPEP133 in three NPC cells
lines (Fig. 2e and f). miPEP133 overexpression inhibited
the proliferation of NPC cell lines (Fig. 2g), increased the
apoptotic cell populations as assessed by AnnexinV and 7-
aminoactinomycin D (7-AAD) staining assay (Fig. 2h and
Fig. 1 Identification of miPEP133. a Schematic graph of the open reading frame (ORF) that encodes miPEP133. The ORF (labeled in red) was
identified in the gene of miR34a, MIR34AHG. b Coomassie blue staining of SDS-PAGE gel that analyzed cell lysate of HEK293 cells transfected with
the control plasmid (−) or the plasmid containing miPEP133 ORF (+). c Mass spectrometry analysis of the 15KDa protein band excised from SDS-
PAGE gel, which confirmed the presence of 4 peptide fragments (#1–4) that match the sequence of miPEP133. d Western blot of miPEP133 in
HEK293 cells transfected with the control plasmid (−) or the plasmid containing miPEP133 ORF (+). β-actin was used as loading control. e The
overexpression of miPEP133 in HEK293 cells was assessed at mRNA level by RT-QPCR. Student’s t-test, *p < 0.001. f Western blot images of
miPEP133 in HEK293 cells transfected with control and 3 siRNAs. siRNAs #1 and #3 knocked down the expression of miPEP133 protein. Student’s
t-test, *p < 0.001. g RT-QPCR data confirmed the knockdown of miPEP133 mRNA by siRNAs #1 and #3. Student’s t-test, *p < 0.5. h Sequencing
result demonstrates the CRISPR/Gas9-mediated partial deletion of miPEP133 ORF. Two clones contain the desired deletions of the ORF, MUT1 (28
bp) and MUT2 (5 bp). Red dotted lines indicate the deleted fragments. i Western blot images of miPEP133 in HEK293 cells. MUT1 and MUT2
clones both lost the expression of miPEP133 protein comparing to the parent cell line (blank) and the cells transfected with empty vectors (CN). j
RT-QPCR of miPEP133 mRNA in the nuclear and cytoplasmic fractions of HEK293 cells. U6 and GAPDH were used as control genes. k Western blot
of miPEP133 protein in normal human tissues
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i), and induced cell cycle arrest at G1 phase (Fig. 2j and k).
In scratch wound healing assays, the migration of C666–1
cells that overexpressed miPEP133 was significantly slower
than the control C666–1 cells (Fig. 2l and m). In transwell
migration assays, fewer cells migrated in the miPEP133-
overexpressing group than the control group (Fig. 2n and
o). In transwell invasion assays, the numbers of C666–1
cells that invaded through the Matrigel were significantly
reduced in the miPEP133-overexpressing group than the
control group (Fig. 2p and q).
miPEP133 inhibits tumor growth in vivo
We next demonstrated the role of miPEP133 as a tumor
suppressor in a xenograft NPC model in vivo. C666–1
cells were subcutaneously injected into the flank of nude
mice. The tumor growth of miPEP133-overexpressing
C666–1 cells was significantly suppressed when com-
pared to that of the control C666–1 cells (Fig. 3a). Three
weeks after the inoculation, tumors collected from the
miPEP133-overexpressing group were significantly
smaller than those in the control group (Fig. 3b and
Fig. 2 Tumor suppressor functions of miPEP133 in nasopharyngeal carcinoma (NPC) cells. a RT-QPCR of miPEP133 mRNA in the nuclear and
cytoplasmic fractions of NP69 cells. U6 and GAPDH were used as control genes. b Representative images of miPEP133 western blot in NP69 and NPC
cell lines. c Quantification of miPEP133 band intensity in western blot. Student’s t-test, **p < 0.005. d RT-QPCR of miPEP133 in normal pharynx and NPC
samples (n = 8). Student’s t-test, *p < 0.05. e Western blot of miPEP133 in three NPC cell lines transfected with control (−) or miPEP133 plasmid (+). f
Quantification of miPEP133 band intensity in western blot. Student’s t-test, **p < 0.005. g Cell growth rates of NPC cell lines. Two-way ANOVA followed
by Sidak’s test, *p < 0.05, **p < 0.005, ***p < 0.001, #p < 0.0001. h Flow cytometry dot plots of C666–1 cells stained with AnnexinV/7-ADD. i
Summarized flow cytometry results of AnnexinV/7-ADD-staining in NPC cells lines. Student’s t-test, *p < 0.05. j Cell cycle status of C666–1 cells
determined by PI staining and flow cytometry. k Summarized flow cytometry results of PI-staining in three NPC cells lines. Student’s t-test, *p < 0.05. l
Representative images of wound healing assay at 0 h and 24 h of control C666–1 cells and the miPEP133-overexpressing C666–1 cells. m
Quantification of wound closure of control C666–1 cells and the miPEP133-overexpressing C666–1 cells at 24 h. Wound closure was presented as the
percentage of wound width that was closed. Student’s t-test, #p < 0.0001. n Representative images of migrating cells in trans-well assay. o
Quantification of migrating cells in the transwell migration assay. Student’s t-test, #p < 0.0001. p Representative images of invading cells in trans-well
assay. q Quantification of invading cells in the transwell invasion assay. Student’s t-test, #p < 0.0001
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Additional file 3: Fig. S3). We confirmed the stable over-
expression of miPEP133 in the tumor tissues at protein
and RNA levels (Fig. 3c and d). Importantly, we identi-
fied the upregulation of miR-34a in the tumors overex-
pressing miPEP133, suggesting that miPEP133 induced
the expression of miR-34a (Fig. 3e).
The immunofluorescence (IF) staining of tumor tissues
demonstrated that the miPEP133-overexpressing tumors
had lower percentages of Ki67-positive proliferating
cells, higher percentages of TUNEL positive apoptotic
cells, and higher percentages of cleaved-caspase-3-posi-
tive apoptotic cells than the control tumors (Fig. 3f, g, h,
and i). This result again supports the role of miPEP133
in inhibiting proliferation and inducing apoptosis in can-
cer cells.
miPEP133 is a prognostic marker that is downregulated
in recurrent and advanced NPC
We evaluated the expression levels of miPEP133 by RT-
QPCR and analyzed their relation to clinical characteris-
tics in 85 cases of NPC. No significant association be-
tween miPEP expression level and sex, age, smoking
history, T staging, N staging, or TNM staging was ob-
served (Additional file 1). The average level of miPEP133
Fig. 3 Tumor suppressor functions of miPEP133 in NPC in vivo. a Tumor growth curves of nude mice that were injected with control C666–1
cells or miPEP133-overexpressing C666–1 cells. Two-way ANOVA test followed by Sidak test, *p < 0.05, **p < 0.005, ***p < 0.0005. b Tumors
xenografts from nude mice. c Western blot images of miPEP133 in the tumors formed by control C666–1 cells and miPEP133-overexpressing
C666–1 cells. d QPCR of miPEP133 in tumors. Student’s t-test, p < 0.01. e QPCR of miR-34a in the tumors. Student’s t-test, p < 0.01. f
Representative images of Ki67, TUNEL, and cleaved caspase-3 staining in tumors from nude mice. DAPI was used to stain the nuclei. g
Quantification of Ki67 positive proliferating cells in mouse tumors. Student’s t-test, ***p < 0.001. h Quantification of TUNEL positive apoptotic cells
in mouse tumors. Student’s t-test, #p < 0.0001. i Quantification of cleaved capsase-3 positive apoptotic cells in mouse tumors. Student’s t-test,
#p < 0.0001. j Decreased mRNA levels of miPEP133 were associated with advanced NPC in 85 human tumor samples. Student’s t-test, *p < 0.05,
**p < 0.005. k mRNA levels of miPEP133 were lower in recurrent NPC. Student’s t-test, **p < 0.005. l mRNA levels of miPEP133 were lower in
metastatic NPC. Student’s t-test, *p < 0.05. m High level of miPEP133 mRNA is a favorable prognostic marker for NPC patient. Kaplan–Meier
analysis and log-rank test were performed (p = 0.014)
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mRNA was higher in stage I/II NPC than that of stage III
or stage IV, and stage III NPC expressed higher levels of
miPEP133 mRNA than stage IV NPC (Fig. 3j). The down-
regulation of miPEP133 mRNA was associated with tumor
recurrence (Fig. 3k) and metastatic diseases (Fig. 3l). We
divided the cases into miPEP133-high and miPEP133-low
groups using the mean of miPEP133 mRNA level as a cut-
off. The Kaplan-Meier survival analysis and. Log-rank test
result suggests that the miPEP133-low group had a signifi-
cantly lower overall survival rate than the miPEP133-high
group (p = 0.014, Fig. 3m). These results indicate that the
downregulation of miPEP133 is a potential prognostic
marker for poor clinical outcomes and advanced diseases.
miPEP133 interacts with mitochondrial heat shock protein
70 (HSPA9) to regulate mitochondrial function
In order to better understand the cellular functions of
miPEP133, we performed immunoprecipitation (IP) of
miPEP133 in HEK293 cells and analyzed the IP product
by mass spectrometry. We identified 18 proteins as
miPEP133 binding partners, the majority of which are
membrane or cytoplasmic proteins (Fig. 4a and Add-
itional file 4). We confirmed the cytoplasmic localization
of miPEP133 in HEK293 and C666–1 cells by transfect-
ing HEK293 and C666–1 cells with a plasmid containing
miPEP133 fused with flag-tag and detecting the flag-
tagged miPEP133 by IF staining (Fig. 4b).
When we analyzed different cellular protein fractions of
HEK293 cells, we identified that miPEP133 was predomin-
antly expressed in the mitochondrial fraction and expressed
at a much lower level in the cytoplasmic fraction (Fig. 4c).
It was noted that one of the partner proteins identified
through mass spectrometry analysis, HSPA9 (also named
mtHsp70, GRP75, or Mortalin) was also predominantly
present in the mitochondrial fraction (Fig. 4c). Using the
mitochondrial fraction as input, we performed co-IP of
miPEP133 and HSPA9 and confirmed their direct inter-
action in the mitochondria (Fig. 4c).
HSPA9 modulates the morphology and function of
mitochondria [25–27]. We hypothesize that through the
interaction with HSPA9 miPEP133 impacts the functions
HSPA9 to regulate mitochondrial morphology and func-
tion. Indeed, the overexpression of miPEP133 in
HEK293 cells significantly decreased the interaction be-
tween HSPA9 and its binding partners, HSP60, TIM44
and VDAC1 (Fig. 4d). miPEP133 overexpression also
caused the downregulation of mitochondrial proteins,
including translocase of outer mitochondrial membrane
20 (TOM20) and the mitochondrial fission/fusion pro-
teins, DRP1, MFN1, and OPA1 (Fig. 4e). The miPEP133-
overexpressing cells showed decreased levels of JC-1
staining than the control cells demonstrating a reduction
of mitochondrial membrane potential (Fig. 4f). IF stain-
ing of TOM20 in the miPEP133-overexpressing cells
confirmed the decreased levels of TOM20 expression
and revealed more fragmented mitochondria and more
shrinking nuclei in the miPEP133-overexpressing cells
than the control cells (Fig. 4g). miPEP133-
overexpressing cells produced significantly lower levels
of ATP than the same numbers of control cells (Fig. 4h).
As previously reported, the inhibition of HSPA9 leads to
mitochondrial proteolytic stress, mitochondrial fragmen-
tation, reduced mitochondrial mass, and increased apop-
tosis [26, 28]. Therefore, our findings demonstrate that
miPEP133 binds to HSPA9 to prevent HSPA9 from
interacting with HSP60, TIM44 and VDAC1, and in-
hibits the normal function of HSPA9 as a mitochondrial
chaperon, which partially accounts for the miPEP133-
induced loss of mitochondrial mass, reduction of mito-
chondrial membrane potential and ATP production, cell
cycle arrest and apoptosis (as illustrated in Fig. 4i).
miPEP133 is transcriptionally regulated by wild-type p53,
but not mutant p53
The expression of miR-34a is regulated by p53 through
the regions proximal to MIR34AHG gene promoter that
contain multiple canonical p53 binding motifs [11, 12].
Since the ORF of miPEP133 is adjacent to miR-34 pre-
cursor as part of miR-34a pri-miRNAs (Fig. 1a), we hy-
pothesized that the expression of miPEP133 was also
regulated by p53 through MIR34AHG promoter. To test
this hypothesis, we first activated p53 with a small-
molecule MDM2 antagonist, nutlin-3a, to assess its im-
pact on miPEP133 expression. Our results showed that
nutlin-3a treatment for 24 h increased the protein levels
of p53 and miPEP133 in HEK293 cells (Fig. 5a and 5b).
In addition, miR-34a and miPEP133 mRNA were both
upregulated by nutlin-3a treatment (Fig. 5c). Second, we
overexpressed wild-type p53 and three common hot-
spot mutations of p53 (R175H, R248W, and R273H) in
HEK293 cells. The overexpressed wild-type p53 induced
the upregulation of miPEP133 protein, but the mutant
p53 did not affect the levels of miPEP133 (Fig. 5d).
These results suggest that wild-type p53 activates
miPEP133 transcription. Mutations can impair the abil-
ity of p53 to regulate miPEP133 transcription.
miPEP133 promotes p53 transcriptional activation
The overexpression of miPEP133 in HEK293 cells did not
change the level of p53 protein (Fig. 5e, f, and g). How-
ever, the overexpression of miPEP133 increased the tran-
scription of miR-34a (Fig. 5h) and the other p53 target
genes, including MDM2, P21, PUMA, and FAS, which are
involved in cell cycle arrest and apoptosis (Fig. 5i). In a
p53 response element reporter assay, we identified that
miPEP133 overexpression enhanced the p53 transcrip-
tional activity (Fig. 5j). Taken together (as illustrated in
Fig. 6k), miPEP133 is transcriptionally activated by wild-
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type p53. Mutations can impair the ability of p53 to in-
duce miPEP133 transcription. miPEP133 in turn enhances
p53 transcriptional activity without changing the level of
p53 protein. miPEP133 induces the transcription of its as-
sociated miRNA, miR-34a.
miPEP133 possesses p53-independent tumor suppressor
functions
In order to examine the function of miPEP133 in differ-
ent cellular contexts, we determined the effect of
miPEP133 overexpression in an ovarian cancer cell line
SKOV3 that is p53 null and Hela cell line that is known
for having p53 inactivated by human papillomavirus
proteins. In SKOV3 and Hela cells, the levels of
miPEP133 protein were significantly lower than that of
HEK293 cells (Fig. 6a). We overexpressed miPEP133 in
SKOV3 and Hela cells as confirmed at protein and RNA
levels (Fig. 6b and c). The overexpression of miPEP133
induced the upregulation of miR-34a in SKOV3 and
Hela cells (Fig. 6d), which is consistent with the observa-
tion in HEK293 and NPC cells. The overexpression of
miPEP133 also significantly decreased the cell viability of
SKOV3 and Hela cells (Fig. 6e) and increased the
AnnexinV positive apoptotic cell population (Fig. 6f).
The JC-1 staining signals were lower in Hela cells that
overexpressed miPEP133 that the control cells
Fig. 4 miPEP133 protein function. a The miPEP133-interacting proteins in HEK293 cells identified by mass spectrometry. b Representative confocal
microscopy images of flag-tag-labeled miPEP133 in the cytoplasm of HEK293 and C666–1 cells. c Western blot images of miPEP133 in cellular fractions
of HEK293 cells and co-IP of miPEP133 and HSPA9 in the mitochondrial fraction. TOM20, DNA topoisomerase 1 (TOP1), and GAPDH were used as
loading controls for mitochondrial, nuclear, and cytoplasmic fractions, respectively. d Co-IP of HSPA9 and its interacting proteins demonstrated the
ability of miEPE133 to block the interaction of HSPA9 to other proteins, including HSP60, TIM44, and VDAC1. e Representative images of western blot
of mitochondrial proteins in from the control HEK293 cells and the miPEP133-overexpressing HEK293 cells. f Summarized flow cytometry result of JC-
1-staining in HEK293 cells transfected with control or miPEP133 plasmid. CCCP-treated HEK293 cells were used as positive control. Student’s t-test,
**p < 0.005. g Representative confocal microscopy images of HEK293 cells transfected with control vector or miPEP133-expressing vector. GFP (green)
indicated the cells were transfected with the vectors. TOM20 (red) labeled the mitochondrial outer membrane. DAPI (blue) was used to stain the
nuclei. Dotted circles indicate the cells with shrinking nucleus. h Cellular ATP level in control and miPEP133-expressing HEK293 cells. Two-way ANOVA,
#p < 0.0001. i Schematic model of miPEP133-regulated mitochondrial integrity and function
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indicating the reduction of mitochondrial membrane
potential (Fig. 6g). These results demonstrated that in
the absence of functional wild-type p53 miPEP133 still
could act as a tumor suppressor to suppress cancer prolif-
eration, induce apoptosis, and decrease mitochondrial
membrane potential. The levels of miPEP133 protein in
ovarian cancer line OVCAR8 and four patient-derived epi-
thelial ovarian cancer cell lines (OVC201, OVC203,
OVC205 and OVC303) were very low or undetectable, in
contrast, two immortalized normal human fallopian tube
epithelial cell lines (FT240 and FT246) expressed high
levels of miPEP133 protein (Fig. 6h). The fallopian tube
epithelial cells have been identified as one of the cell-of-
origins for high-grade serous ovarian carcinoma that is
the most common type of ovarian cancer. We also con-
firmed the loss of miPEP133 in eight tumor tissue samples
from epithelial ovarian cancer patients (Fig. 6i). These re-
sults suggest that miPEP133 is also a tumor suppressor in
ovarian cancer.
Discussion
In this study, we have identified a novel microprotein
that is encoded by an ORF in the precursor of miR-34a.
This microprotein, namely miPEP133, mainly localizes
in the mitochondria and plays a role as a tumor suppres-
sor with the activity to induce cell cycle arrest, cell
growth inhibition, and apoptosis in cancer cells in
addition to slowing down cancer cell migration and in-
vasion. We revealed the mechanisms of its function that
involves interacting with mitochondrial chaperon
HSP9A and disrupting the interaction of HSP9A with
other proteins. Our findings demonstrated the tumor
suppressor activity of miPEP133 and its potential value
as a prognostic marker and therapeutic target.
miPEPs are more common in plant, but rare in ani-
mals. miPEP133 is the first miPEP that is identified in
the pri-miRNA of tumor suppressor miRNA in human.
It shares the same promoter as its associated miRNA,
miR-34a. Therefore, the expression patterns of
Fig. 5 miPEP133 and wild-type p53 reciprocal regulation. a Representative western blot images of p53 and miPEP133 in HEK293 cells untreated or
treated with Nutlin3a. GAPDH was used as loading control. b Quantification of p53 and miPEP133 band intensity in western blot. Student’s t-test,
***p < 0.0005, #p < 0.0001. c RT-QPCR of miPEP133 and miR-34a mRNA in HEK293 cells untreated or treated with Nutlin3a. Student’s t-test, #p < 0.0001.
d Representative western blot images of wild-type (WT) or mutant p53 and miPEP133 in HEK293 cells transfected with WT or mutant p53 plasmids.
GAPDH was used as loading control. e Representative western blot images of p53 and miPEP133 in control and miPEP133-overexpressing HEK293
cells. GAPDH was used as loading control. f Quantification of p53 and miPEP133 band intensity in western blot. Student’s t-test, **p < 0.005. g RT-QPCR
of miPEP133 mRNA in control and miPEP133-overexpressing HEK293 cells. Student’s t-test, *p < 0.05. h RT-QPCR of miR-34a in control and miPEP133-
overexpressing HEK293 cells. Student’s t-test, *p < 0.05. i RT-QPCR of p53 target genes in control and miPEP133-overexpressing HEK293 cells. Two-way
ANOVA followed by Sidak’s test, **p < 0.005, ***p < 0.001, #p < 0.0001. j p53 response element luciferase reporter assay in control and miPEP133-
overexpressing HEK293 cells. Student’s t-test, *p < 0.05. k Schematic model of the reciprocal regulation between miPEP133 and p53
Kang et al. Molecular Cancer          (2020) 19:143 Page 10 of 14
miPEP133 are similar to miR-34a. miPEP133 and miR-
34a are both downregulated in tumor tissues and both
regulated by p53. The other inducers of miR-34a, such
as ELK1 and TAp73 [29], may also induce miPEP133 ex-
pression, which is yet to be determined in the future
studies. The target genes of miR-34a are involved in
oncogenic signaling pathways, such as cell proliferation
(e.g. cyclins, cyclin-dependent kinases, MYCN,
NOTCH1, and MDMX), anti-apoptosis (e.g. BCL2 and
SIRT1), cancer stem-like cell properties (e.g. CD44,
NANOG, and SOX2), metastasis (e.g. SNAI1 and MET),
and immune evasion (e.g. PD-L1). miPEP133 can pro-
mote the transcription of miR-34a to enhance the silen-
cing of these miR-34a-targeted genes. We have observed
the miPEP133-induced downregulation of ATF3,
AXIN2, CDKN1A, DLL1, E2F1, E2F2, FOXP1, JAG1,
MYCN, SIRT1, and SOX2, which are miR-34a-targeted
genes (data not shown).
The mechanisms underlying miPEP133-induced ex-
pression of miR-34a may be explained by different co-
existing mechanisms under different cellular contexts. In
cells with wild-type functional p53, such as HEK293
cells, miPEP133 can disrupt mitochondrial functions,
which activates wild-type p53 transcriptional activity
consequently inducing miR34a expression. In the mean-
time, the miPEP133-induced mitochondrial dysfunction
can activate other transcriptional regulators of miR-34a,
such as TAp73, to directly bind to the promoter of
miR34a [29, 30]. The latter mechanism may be respon-
sible for the miPEP133-induced upregulation of miR-34a
in p53-null cancer cells like ovarian cancer cell line
SKOV3 [31] and cancer cells without functional wild-
type p53. p53 mutation is very common in ovarian can-
cer, particularly in high-grade serous ovarian carcinoma.
NPC cells usually have wild-type p53, however, NPC is
highly associated with Epstein-Bar virus that can inacti-
vate p53 [32]. Cervical cancer Hela cell line is also
known for having p53 inactivated by human papilloma-
virus proteins [33]. Our findings demonstrated the p53-
dependent and p53-independent tumor suppressor roles
of miPEP133 in different cellular contexts with diverse
p53 status.
HSPA9 is involved in stress response, antigen process-
ing, control of cell proliferation, differentiation and
tumorigenesis [34]. HSPA9 has anti-apoptotic and pro-
proliferative activities [35, 36]. Increasing levels of
HSPA9 permit cells to survive lethal conditions [37–39].
HSPA9 influences the function, dynamics, morphology,
Fig. 6 miPEP133 has p53-independent functions. a Representative western blot images of miPEP133 in ovarian cancer cell line SKOV3 and
cervical cancer cell line Hela. GAPDH was used as loading control. b Representative western blot images of miPEP133 in control and miPEP133-
overexpressing SKOV3 and Hela cells. c RT-QPCR of miPEP133 in control and miPEP133-overexpressing SKOV3 and Hela cells. Student’s t-test, *p <
0.01, #p < 0.0001. d RT-QPCR of miR-34a in control and miPEP133-overexpressing SKOV3 and Hela cells. Student’s t-test, *p < 0.01. e Cell growth
rates of SKOV3 and Hela cells. Two-way ANOVA followed by Sidak’s test, *p < 0.05, **p < 0.005, ***p < 0.001, #p < 0.0001. f Flow cytometry dot
plots of SKOV3 and Hela cells transfected with control or miPEPqee plasmid and stained with AnnexinV/7-ADD. g Summarized flow cytometry
result of JC-1-staining in Hela cells transfected with control or miPEP133 plasmid. CCCP-treated Hela cells were used as positive control. Student’s
t-test, **p < 0.005. h Representative western blot images of miPEP133 in patient-derived ovarian cancer cell lines, OVC201, OVC203, OVC205 and
OVC303. Normal human fallopian tube epithelial cell lines, FT240 and FT246, were used as noncancerous control cells. GAPDH was used as
loading control. i Representative western blot images of miPEP133 in ovarian cancer samples (T1-T8. Human normal uterus tissue protein lysate
was used as a positive control in western blot. β-actin was used as loading control
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and homeostasis of mitochondria as the only ATPase
component of the mitochondrial protein import machin-
ery [35, 40, 41]. Mitochondrial protein precursors are
chaperoned by HSPA9 into the mitochondrial matrix
with the assistance of co-chaperones [42]. HSPA9 forms
a complex with HSP60 and floats freely in the mitochon-
drial matrix to regulate protein folding [43]. HSPA9 also
binds the translocase of the mitochondrial inner and
outer membranes [44, 45]. Their complexes control the
translocation of precursor proteins and their distribution
in the matrix and across the mitochondrial membranes
[46–48]. HSPA9-VDAC1 complex modulates voltage-
dependent anion-selective channel properties [49]. The
interaction with miPEP133 prevents HSPA9 from acting
as a chaperon and interacting with its partner proteins,
which demonstrates a new mechanism for regulating
mitochondrial morphology and function.
Conclusion
We have identified a novel microprotein encoded by the
precursor of miR-34a, miPEP133. It is a tumor suppres-
sor that induces apoptosis in cancer cells and inhibits
their migration and invasion. Low miPEP133 expression
is a prognostic marker of advanced and metastatic NPC.
We demonstrated the reciprocal regulation between
wild-type p53 and miPEP133. miPEP133 localizes in the
mitochondria to prevent HSPA9 from interacting with
its binding partners and regulate mitochondrial function.
A better understanding of miPEP133 function and regu-
lation will provide a new biomarker and potential thera-
peutic target for improving the prognosis and treatment
of NPC and other cancers. Our work also sets a founda-
tion for understanding the roles of miPEPs in the
tumorigenesis of all cancer types.
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